BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 1488870)

  • 1. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
    Skotnicki AB; Wolska-Smoleń T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
    Appelbaum FR
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
    Litam PP; Landaw SA; Zamkoff KW
    Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 11. [Interferon-alpha in the treatment of myeloproliferative syndromes].
    Ballarino P; Castello G; Lerza R
    Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-alpha therapy in chronic myeloid leukemia].
    Lutz D
    Wien Med Wochenschr; 1993; 143(16-17):416-9. PubMed ID: 8273364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic myeloproliferative syndromes].
    de Ozalla CB; García Suárez J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
    Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
    Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI; Vardiman JW
    Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
    Spivak JL
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.